EFFICACY AND SAFETY OF LAROTRECTINIB IN PAEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER: AN EXTENDED FOLLOW-UP

被引：0

作者：

Zwaan, C. Michel ^{[1
]}

Van Tilburg, Cornelis ^{[2
,3
]}

Doz, Francois ^{[4
,5
]}

Albert, Catherine ^{[6
]}

Blattmann, Claudia ^{[7
]}

Geoerger, Birgit ^{[8
]}

Dubois, Steven ^{[9
]}

Federman, Noah ^{[10
]}

Mascarenhas, Leo ^{[11
]}

Nagasubramanian, Rama ^{[12
]}

Pappo, Alberto ^{[13
]}

Watt, Tanya ^{[14
]}

Norenberg, Ricarda ^{[15
]}

Dima, Laura ^{[16
]}

De la Cuesta, Esther ^{[17
]}

Laetsch, Theodore ^{[18
]}

Xu, Ruihua ^{[19
]}

机构：

[1] Princess Maxima Ctr Pediat Oncol, Stem Cell Transplantat Unit, Utrecht, Netherlands

[2] ErasmusMC Sophias Childrens Hosp, Pediat Oncol, Rotterdam, Netherlands

[3] Heidelberg Univ Hosp, German Canc Res Ctr DKFZ, Hopp Childrens Canc Ctr Heidelberg kitz, Heidelberg, Germany

[4] SIREDO Oncol Ctr Care, Inst Curie, Innovat & Res Children & AYA Canc, Paris, France

[5] Univ Paris Cite, Pediat, Paris, France

[6] Univ Washington Sch Med, Seattle Childrens Hosp, Dept Hematol Oncol, Seattle, WA USA

[7] Olgahospital, Dept Haematol & Oncol, Stuttgart, Germany

[8] Univ Paris Saclay, Gustave Roussy Canc Ctr, Dept Pediat & Adolescent Oncol, Villejuif, France

[9] Dana Farber Hosp, Childrens Canc & Blood Disorders Ctr, Boston, MA USA

[10] David Geffen Sch Med, UCLA Jonsson Comprehensive Canc Ctr, Pediat Hematol Oncol, Los Angeles, CA USA

[11] Univ Southern Calif Keck Sch Med, Childrens Hosp Angeles, Canc & Blood Dis Inst, Dept Hematol Oncol, Los Angeles, CA USA

[12] Childrens Hosp, Dept Hematol Oncol, Orlando, FL USA

[13] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN USA

[14] Univ Texas, SouthWestern Med Ctr, Dept Pediat, Austin, TX USA

[15] Chrestos Concept GmbH Co KG, Essen, Germany

[16] Bayer HealthCare SAS, Med Affairs, Garenne Colombes, France

[17] Bayer HealthCare Pharmaceut Inc, Oncol, Whippany, NJ USA

[18] Univ Pennsylvania, Childrens Hosp Philadelphia, Dev Therapeut Program, Philadelphia, PA USA

[19] Sun Yat sen Univ Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China

来源：

PEDIATRIC BLOOD & CANCER | 2022年 / 69卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP379

引用

页码：S324 / S325

页数：2

共 50 条

[21] Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An updated analysis
Andre, T.
Hong, D.
Deeken, J.
Italiano, A.
Liu, T.
Burcoveanu, D.
Norenberg, R.
Mussi, C.
Xu, R.
Drilon, A.
Shen, L.
ANNALS OF ONCOLOGY, 2023, 34 : S12 - S13
[22] Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer
Federman, Noah
McDermott, Ray
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (10) : 931 - 939
[23] Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer
Rosen, Ezra Y.
Italiano, Antoine
Juric, Dejan
Reeves, John A.
Dima, Laura
Brega, Nicoletta
Drilon, Alexander
CANCER RESEARCH, 2021, 81 (04)
[24] Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Qi, Changsong
Shen, Lin
Andre, Thierry
Chung, Hyun Cheol
Cannon, Timothy L.
Garralda, Elena
Italiano, Antoine
Rieke, Damian T.
Liu, Tianshu
Burcoveanu, Domnita-Ileana
Neu, Natascha
Mussi, Chiara E.
Xu, Rui-Hua
Hong, David S.
Drilon, Alexander
Berlin, Jordan
EUROPEAN JOURNAL OF CANCER, 2025, 220
[25] Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Berlin, Jordan
Hong, David S.
Deeken, John F.
Boni, Valentina
Oh, Do-Youn
Patel, Jyoti D.
Nanda, Shivani
Brega, Nicoletta
Childs, Barrett H.
Hyman, David Michael
Drilon, Alexander E.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[26] Efficacy and safety of larotrectinib in patients with TRK fusion gastrointestinal cancer
Leyvraz, S.
Berlin, J.
Hong, D. S.
Deeken, J.
Valentina, B.
Oh, D. -Y.
Patel, J.
Nanda, S.
Brega, N.
Childs, B. H.
Hyman, D. M.
Drilon, A.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 231 - 232
[27] Larotrectinib Efficacy and Safety in Pediatric Patients with TRK Fusion Cancer
Koga, Yuhki
PEDIATRIC BLOOD & CANCER, 2020, 67
[28] LAROTRECTINIB EFFICACY AND SAFETY IN PEDIATRIC PATIENTS WITH TRK FUSION CANCER
Albert, Catherine
Geoerger, Birgit
van Tilburg, Cornelis
DuBois, Steven
Federman, Noah
Nagasubramanian, Ramamoorthy
Doz, Francois
Orbach, Daniel
Bielack, Stefan
Shukla, Neerav
Turpin, Brian
Casanova, Michela
Spunt, Sheri
Nanda, Shivani
Childs, Barrett
Pappo, Alberto
Laetsch, Theodore
Mascarenhas, Leo
PEDIATRIC BLOOD & CANCER, 2020, 67 : S10 - S11
[29] Larotrectinib Efficacy and Safety in Pediatric Patients with TRK Fusion Cancer
Geoerger, B.
van Tilburg, C.
DuBois, S.
Albert, C.
Federman, N.
Nagasubramanian, R.
Doz, F.
Orbach, D.
Bielack, S.
Shukla, N.
Turpin, B.
Casanova, M.
Spunt, S.
Qamoos, H.
Cox, M.
Nanda, S.
Childs, B.
Pappo, A.
Laetsch, T.
Mascarenhas, L.
PEDIATRIC BLOOD & CANCER, 2019, 66 : S65 - S66
[30] Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC)
Cabanillas, Maria E.
Lin, Jessica Jiyeong
Brose, Marcia S.
McDermott, Raymond S.
Almubarak, Mohammed
Bauman, Jessica R.
Casanova, Michela
Kummar, Shivaani
Lee, Se-Hoon
Leyvraz, Serge
Oh, Do-Youn
Shen, Lin
Norenberg, Ricarda
Bernard-Gauthier, Vadim
Mussi, Chiara E.
Hong, David S.
Drilon, Alexander E.
Waguespack, Steven G.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →